Elite Pharmaceuticals Shares Surge Ahead of Market Open

The specialty pharmaceutical company's stock jumped over 4% in pre-market trading.

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) opened significantly higher on Tuesday, rising from a previous close of $0.44 to $0.46 at the start of trading. The stock went on to trade at $0.4651, with a volume of 122,088 shares. Elite Pharmaceuticals is a U.S.-based specialty pharmaceutical company that focuses on complex drug formulations and seeks to address unmet medical needs.

Why it matters

The gap-up in Elite Pharmaceuticals' share price suggests increased investor interest or positive news about the company's operations or pipeline. As a specialty pharmaceutical firm, Elite's performance is closely watched by industry analysts and investors seeking opportunities in the complex drug development and manufacturing space.

The details

Elite Pharmaceuticals has a market capitalization of $487.99 million and a price-to-earnings ratio of 45.36. The company's stock has a beta of 0.33, indicating relatively low volatility compared to the broader market. Elite Pharmaceuticals is headquartered in Houston, Texas and focuses on developing and marketing both branded and generic pharmaceutical products, with a emphasis on complex dosage forms like injectables, sterile formulations, and oncology therapies.

  • Elite Pharmaceuticals' shares opened at $0.46 on Tuesday, February 17, 2026, up from a previous close of $0.44.

The players

Elite Pharmaceuticals, Inc.

A U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products, with a focus on complex dosage forms and addressing unmet medical needs.

Got photos? Submit your photos here. ›

The takeaway

The surge in Elite Pharmaceuticals' share price on Tuesday suggests growing investor confidence in the company's ability to navigate the complex pharmaceutical landscape and capitalize on opportunities in specialty drug development and manufacturing.